Benefits
Mild Cognitive Impairment 16-week trial
A randomized double-blind placebo-controlled trial in adults with mild cognitive impairment used 3 g/day fruiting body powder for 16 weeks. Significant cognitive scale improvements appeared at weeks 8, 12, and 16, with effects building over time. Benefits faded within 4 weeks of stopping, suggesting continuous use is needed.
Early Alzheimer's 49-week pilot trial
A pilot trial of erinacine A-enriched mycelium (350 mg capsules standardized to 5 mg/g erinacine A) over 49 weeks in patients at risk of early Alzheimer's showed cognitive improvements versus placebo decline. Importantly, this trial used standardized erinacine A, not generic mycelium.
Older Japanese adults 12-week trial
A 12-week randomized trial in older adults reported significant cognitive function improvement and prevention of cognitive deterioration on standard cognitive scales. Adds geographic and demographic generalizability for the cognitive-support indication.
Erinacines vs hericenones chemistry distinction
Both compound classes stimulate NGF synthesis in cell culture, but they behave differently in living tissue. Hericenones failed to promote NGF gene expression in human cell models; erinacine A successfully upregulated NGF in animal brain regions. The scientific rationale for standardized preparations over generic Lion's Mane.
Mycelium-on-grain dilution problem
Most commercial mycelium-on-grain Lion's Mane products lack meaningful erinacine concentrations — the grain substrate dilutes the bioactives. Such products provide neither hericenones nor sufficient erinacines. Trial-matched preparations are fruiting body extracts or erinacine A-standardized mycelium.
Mixed acute effects in healthy adults
An acute trial of 3 g 10:1 fruiting body extract in healthy 18-35 year olds showed no global cognitive or mood improvement, with only a motor task improvement at 90 minutes. Honest mixed acute results: benefits likely require chronic supplementation over weeks rather than single doses.
Polysaccharides and terpenoids beyond NGF
Fruiting body extracts are concentrated in polysaccharides and terpenoids with antioxidant and immunomodulatory activities beyond NGF stimulation. Supports the broader rationale for fruiting body preparations over mycelium-on-grain.
Mechanism of action
Erinacine A NGF upregulation (mycelium)
Erinacine A successfully upregulates NGF gene expression in vivo in rat locus coeruleus and hippocampus. This is the distinguishing in vivo neurotrophic mechanism for mycelium-localized compounds.
Hericenone NGF synthesis stimulation (fruiting body)
Hericenones stimulate NGF synthesis and NGF-induced neurite outgrowth in vitro. However, hericenones failed to promote NGF gene expression in 1321N1 human astrocytomas — the in vivo translation may be weaker than the mycelium-localized erinacines. Fruiting body benefits likely arise from a combination of hericenones plus polysaccharides and terpenoids.
Erinacine A neuroprotection (preclinical)
Erinacine A confers neuroprotective effects and attenuates oxidative stress in mouse models of stroke, Alzheimer's, Parkinson's, depression, and aging. Multi-disease preclinical evidence underlies the neuroprotection rationale.
Polysaccharides and terpenoids (fruiting body)
The fruiting body is concentrated in polysaccharides and terpenoids with antioxidant and immunomodulatory activities. Supports the broader cognitive and longevity rationale beyond NGF stimulation.
Continuous supplementation requirement
Cognitive scores declined within 4 weeks of supplementation discontinuation. Effects appear to require continuous administration rather than persisting after a treatment course.
Strain and extraction method dependency
Different strains and extraction methods produce different bioactive profiles. Generic 'Lion's Mane' on a label does not reliably identify a clinical-evidence-matched preparation — strain origin (mycelium vs fruiting body) and standardization markers (erinacine A content) are the practical purchasing criteria.
Clinical trials
Clinical evidence on Hericium erinaceus (Mycelium vs Fruiting Body — Strain Specifics) for the indications and outcomes described.
Clinical population described in trial publication.
Mori K et al. 2009. Randomized double-blind placebo-controlled trial in 30 Japanese adults aged 50-80 with mild cognitive impairment. 3 g/day fruiting body dry powder vs placebo for 16 weeks. Significant HDS-R improvements at weeks 8, 12, and 16, with effects increasing over time. Cognitive scores declined within 4 weeks post-discontinuation. Foundational landmark trial — defines the fruiting body 3 g/day dose for cognitive applications.
Pilot double-blind clinical trial of erinacine A-enriched H. erinaceus mycelium (EAHE: 3 × 350 mg capsules, 5 mg/g erinacine A) for 49 weeks in patients at risk of early Alzheimer's disease.
Clinical population described in trial publication.
Pilot double-blind clinical trial of erinacine A-enriched H. erinaceus mycelium (EAHE: 3 × 350 mg capsules, 5 mg/g erinacine A) for 49 weeks in patients at risk of early Alzheimer's disease. EAHE group showed significant MMSE improvement vs placebo cognitive decline. CASI, IADL, and contrast sensitivity outcomes favored EAHE. Defines the standardized erinacine A mycelium preparation evidence base — distinct from generic mycelium products.
12-week clinical trial in older Japanese adults reported significant cognitive function improvement and prevention of cognitive deterioration measured by MMSE.
Clinical population described in trial publication.
12-week clinical trial in older Japanese adults reported significant cognitive function improvement and prevention of cognitive deterioration measured by MMSE. Adds geographic and demographic generalizability for the cognitive-support indication.
2025 acute double-blind clinical trial, 3 g of 10:1 fruiting body extract in 18 healthy 18-35 year olds.
Clinical population described in trial publication.
2025 acute double-blind clinical trial, 3 g of 10:1 fruiting body extract in 18 healthy 18-35 year olds. No significant global cognitive or mood improvement; pegboard test showed improvement at 90 minutes. Mixed acute findings suggesting chronic supplementation may be required for clinically meaningful effects — consistent with effects emerging over weeks 8-16.